CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 301–400 of 1,725
Cromer, M. K., Majeti, K. R., Rettig, G. R., Murugan, K., Kurgan, G. L., Bode, N. M., Hampton, J. P., Vakulskas, C. A., Behlke, M. A., & Porteus, M. H. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.011 · Cited by 42
Chemical Evolution of Amphiphilic Xenopeptides for Potentiated Cas9 Ribonucleoprotein Delivery
Lin, Y., Luo, X., Burghardt, T., Dorrer, S., Höhn, M., Wagner, E., & Lächelt, U. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01902 · Cited by 49
Liver‐directed gene therapy for inherited metabolic diseases
Baruteau, J., Brunetti‐Pierri, N., & Gissen, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12709 · Cited by 48
“19 Base editing and prime editing have shown proof of concept in a preclinical model of phenylketonuria (PKU).”
BackgroundGoyal, P., Maurer, M. S., & Roh, J. D. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.02.021 · Cited by 57
A battery-free nanofluidic intracellular delivery patch for internal organs
Yin, D., Wang, P., Hao, Y., Yue, W. W., Jiang, X., Yao, K., Wang, Y., Hang, X., Xiao, A., Zhou, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08943-x · Cited by 58
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Rim, J. H., Gopalappa, R., & Gee, H. Y. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114592 · Cited by 51
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 49
Focus on your locus with a massively parallel reporter assay
McAfee, J. C., Bell, J., Krupa, O., Matoba, N., Stein, J. L., & Won, H. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09461-x · Cited by 43
“Moreover, causal variant identification provides the intriguing possibility of developing therapeutics by reversing pathological transcriptional mechanisms or genetically modifying causal variants [17, 18].”
BackgroundLipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing
Onuma, H., Sato, Y., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.008 · Cited by 51
Microfluidic Platform Enables Shearless Aerosolization of Lipid Nanoparticles for mRNA Inhalation
Kim, J., Jozić, A., Bloom, E., Jones, B., Marra, M., Murthy, N. T. V., Eygeris, Y., & Sahay, G. (2024) · ACS Nano · doi:10.1021/acsnano.4c00768 · Cited by 55
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
Jonker, A. H., Tãtaru, E.-A., Graeßner, H., Dimmock, D., Jaffé, A., Baynam, G. S., Davies, J. O. J., Mitkus, S., Iliach, O., Horgan, R., et al. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01059-3 · Cited by 53
“Healthcare products Regulatory Agency (MHRA), FDA and European Medicines Agency (EMA) for two haemoglobinopathies, sickle cell disease and beta thalassaemia 49,50 .”
Endo/Lysosomal-Escapable Lipid Nanoparticle Platforms for Enhancing mRNA Delivery in Cancer Therapy
Wang, J., Chen, R., Xie, Y., Qin, X., Zhou, Y., & Xu, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070803 · Cited by 56
“…protein replacement in monogenic disorders like methylmalonic acidemia and cystic fibrosis [5]. mRNA-encoded gene-editing tools such as CRISPR-Cas9 are being used for precise genomic modifications, with applications in treating amyloidosis and lowering LDL cholesterol through PCSK9 editing [6,7].”
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges
Falabella, M., Minczuk, M. A., Hanna, M. G., Viscomi, C. F., & Pitceathly, R. D. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00715-9 · Cited by 48
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
RNA and Protein Delivery by Cell‐Secreted and Bioengineered Extracellular Vesicles
Wang, B. Z., Luo, L. J., & Vunjak‐Novakovic, G. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101557 · Cited by 50
Gene therapy for monogenic disorders: challenges, strategies, and perspectives
Zhang, Y., & Wu, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.08.001 · Cited by 46
Song, N., Chu, Y., Li, S., Dong, Y., Fan, X., Tang, J., Guo, Y., Teng, G., Yao, C., & Yang, D. (2023) · Science Advances · doi:10.1126/sciadv.adi3602 · Cited by 42
Palacios, A. M., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1342193 · Cited by 56
Li, Z., Amaya, L., Ee, A., Wang, S. K., Ranjan, A., Waymouth, R. M., Chang, H. Y., & Wender, P. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c02704 · Cited by 41
Li, S., YU, J. J., Shen, Y., Xiong, B., Zhao, D., Xu, W., Zhang, S., Guan, X., Liu, Y., Shan, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56755-4 · Cited by 51
“Moreover, commonly used vectors like adeno-associated virus (AAV), lentivirus and lipid nanoparticles of non-viral vectors have limited loading capacity and systemic toxicity 22,23 .”
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
Gillmore, J. D., Gane, E. J., Täubel, J., Pilebro, B., Echaniz‐Laguna, A., Kao, J., Litchy, W. J., Shahda, S., Haagensen, A., Walsh, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510209 · Cited by 51
Self-citationCRISPR‐driven diagnostics: Molecular mechanisms, clinical efficacy and translational challenges
Wang, Z., Wang, Q., Zhang, J., Li, B., Li, Y., Chen, Z., Guo, D., & Feng, S. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70482 · Cited by 60
“48 The technology has received FDA approval for an Investigational New Drug (IND) application and is currently undergoing related clinical trials.”
The Bibliometric Landscape of Gene Editing Innovation and Regulation in the Worldwide
Wei, X., Pu, A., Liu, Q., Hou, Q., Zhang, Y., An, X., Long, Y., Jiang, Y., Dong, Z., Wu, S., et al. (2022) · Cells · doi:10.3390/cells11172682 · Cited by 42
“…[40] Functional genomics in human cells Anthrax and diphtheria toxin host genes [41] Human autologous CD34+ cells BCL11A [42] Human hepatocytes TTR [43] Human fibroblast APP [44] Mouse acute myeloid leukemia cell RPA3,Brd4,Smarca4,Eed, Suz12 and Rnf20 [45] 204 human cancer cell lines 18,009 genes…”
BackgroundGEARS: Predicting transcriptional outcomes of novel multi-gene perturbations
Roohani, Y., Huang, K., & Leskovec, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.12.499735 · Cited by 40
Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients
Solignac, J., Delmont, É., Fortanier, É., Attarian, S., Mancini, J., Daniel, L., Ion, I. M., Ricci, J., Robert, T., Habib, G., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac118 · Cited by 40
Current advances in gene therapy of mitochondrial diseases
Soldatov, V. O., Kubekina, M. V., Skorkina, M. Y., Белых, А. Е., Egorova, T. V., Корокин, М. В., Pokrovskiy, M. V., Deykin, A. V., & Angelova, P. R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03685-0 · Cited by 48
“Several CRISPR/Cas9 based in vivo interventions have already reached the first clinical trials [44, 45].”
BackgroundDing, L., Zhang, X., Yu, P., Peng, F., Sun, Y., Wu, Y., Luo, Z., Li, H., Zeng, Y., Wu, M., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.011 · Cited by 44
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
Tomasoni, D., Bonfioli, G. B., Aimo, A., Adamo, M., Canepa, M., Inciardi, R. M., Lombardi, C., Nardi, M., Pagnesi, M., Riccardi, M., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1154594 · Cited by 42
Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
“The results demonstrated mild side effects and a significant dose-dependent reduction in serum TTR protein levels [106].”
BackgroundImproving access to gene therapy for rare diseases
Fox, T. A., & Booth, C. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050623 · Cited by 45
Xue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 43
Shariati, L., Esmaeili, Y., Rahimmanesh, I., Babolmorad, S., Ziaei, G., Hasan, A., Boshtam, M., & Makvandi, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116933 · Cited by 47
Al-Ouqaili, M. T. S., Ahmad, A., Jwair, N. A., & Al-Marzooq, F. I. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1588446 · Cited by 55
Transthyretin amyloid cardiomyopathy: from cause to novel treatments
Fontana, M., Aimo, A., Emdin, M., Porcari, A., Solomon, S., Hawkins, P., & Gillmore, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf667 · Cited by 42
“40 In a Phase 1, open-label trial, 36 patients with ATTR-CM received a single intravenous infusion of nex-z.”
Self-citationmRNA-mediated delivery of gene editing tools to human primary muscle stem cells
Stadelmann, C., Francescantonio, S. D., Marg, A., Müthel, S., Spuler, S., & Escobar, H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.016 · Cited by 43
“The first clinical trial of systemic in vivo mRNA-based delivery of CRISPR/Cas9 components is presently performed to target the liver of patients with hereditary transthyretin amyloidosis.(31,32) However, skeletal muscle accounts for approximately 40% of adult body mass, and systemic LNP-mediated mRNA delivery to targ…”
BackgroundStrategies to target the cancer driver MYC in tumor cells
Weber, L. I., & Hartl, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142111 · Cited by 52
Efficient mRNA delivery to resting T cells to reverse HIV latency
Cevaal, P. M., Kan, S., Fisher, B. M., Moso, M. A., Tan, A., Liu, H., Ali, A., Tanaka, K., Shepherd, R. A., Kim, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60001-2 · Cited by 38
“1 – 0.6 mg/kg of mRNA waswell-tolerated in humans 2,53,54 .”
InfluentialAdvances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 41
“Recent clinical trial data displayed great promise in treating patients with hereditary trans-thyretin amyloidosis 9 or SCD and b -thalassemia 10 using in vivo CRISPR-Cas9 delivery or ex vivo CRISPR-Cas9-modified hematopoietic stem and progenitor cells (HSPCs).”
CRISPR/Cas9-based gene-editing technology for sickle cell disease
Ma, L., Yang, S., Peng, Q., Zhang, J., & Zhang, J. (2023) · Gene · doi:10.1016/j.gene.2023.147480 · Cited by 55
Building CRISPR Gene Therapies for the Central Nervous System: A Review
Salomonsson, S. E., & Clelland, C. D. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4983 · Cited by 46
Im, S. H., Jang, M., Park, J., & Chung, H. J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02427-2 · Cited by 46
“Particularly, the CRISPR/Cas9 systems has been shown promising as a cure for genetic diseases [4–6] and cancer [7, 8], with several clinical trials ongoing.”
BackgroundLiu, L., Kim, J.-H., Li, Z., Sun, M., Trent, N., Tang, Y. J., Mcintosh, E., Karve, S., & DeRosa, F. (2025) · Nanoscale · doi:10.1039/d5nr00433k · Cited by 50
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 56
“230 Finally, the potential for cell reprogramming in areas such as chimeric antigen receptor (CAR) T cell therapy is immense.”
mRNA and gene editing: Late breaking therapies in liver diseases
Zabaleta, N., Torella, L., Weber, N. D., & González‐Aseguinolaza, G. (2022) · Hepatology · doi:10.1002/hep.32441 · Cited by 40
“[9] In a separate study, patients suffering from transthyretin amyloidosis (ATTR) were treated with CRISPR- based gene editing technology, with extremely positive interim Phase 1 results.[10] In this review we discuss recent experimental studies on the use of mRNA- based therapies and different gene editing strategies…”
BackgroundMethodInfluentialThe 2019 and 2021 International Workshops on Alport Syndrome
Daga, S., Ding, J., Deltas, C. C., Savige, J., Lipska-Ziętkiewicz, B. S., Hoefele, J., Flinter, F. A., Gale, D. P., Евгеньевна, А. М., Kai, H., et al. (2022) · European Journal of Human Genetics · doi:10.1038/s41431-022-01075-0 · Cited by 37
Performance of nanoparticles for biomedical applications: The in vitro / in vivo discrepancy
Berger, S., Berger, M., Bantz, C., Maskos, M., & Wagner, E. (2022) · Biophysics Reviews · doi:10.1063/5.0073494 · Cited by 46
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing Tool
Li, T., Zhang, L., Lu, T., Zhu, T., Feng, C., Gao, N., Liu, F., Yu, J., Chen, K., Zhong, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206517 · Cited by 43
Genome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 48
“An LNP-mediated CRISPR/Cas9 system (NTLA-2001 developed by Intelliatherapeutics)hasbeendevelopedtoreduceTTRproteinlevelsinthe treatmentofhATTRamyloidosiswithpolyneuropathyortransthyretin amyloidosis-related cardiomyopathy (NCT04601051) 163,164 .”
Targeted delivery strategies: The interactions and applications of nanoparticles in liver diseases
Meng, X., Zhu, G., Yang, Y., & Sun, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116702 · Cited by 41
Gene therapy for cardiac diseases: methods, challenges, and future directions
Grisorio, L., Bongianino, R., Gianeselli, M., & Priori, S. G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae207 · Cited by 37
Durán‐Vinet, B., Araya‐Castro, K., Calderón, J. F., Vergara, L. F., Weber, H. L., Retamales, J., Araya-Castro, P., & Leal, P. (2021) · Cancers · doi:10.3390/cancers13184640 · Cited by 40
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 41
“TTR knockdown was demonstrated to be persistent after a single dosage in preclinical trials with minimal adverse events, thereby highlighting the efficacy of this strategy in ATTR therapy [219].”
BackgroundNano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 42
Loo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 41
Self-citationGene Editing Technologies to Target HBV cccDNA
Martínez, M. G., Smekalova, E. M., Combe, E., Gregoire, F. M., Zoulim, F., & Testoni, B. (2022) · Viruses · doi:10.3390/v14122654 · Cited by 39
Olivotto, I., Udelson, J. E., Pieroni, M., & Rapezzi, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac764 · Cited by 38
Lipid Nanoparticle-Enabled Intracellular Delivery of Prime Editors
Herrera‐Barrera, M., Gautam, M., Lokras, A. G., Vlasova, K. Y., Foged, C., & Sahay, G. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00833-2 · Cited by 39
“Cas9 mRNA-based gene editing approaches using LNPs are being vigorously explored clinically for liver [29, 30] and non-liver [31] targets.”
BackgroundChen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 41
“69,70 In this study, we demonstrate the use of LNPs for the co-delivery of chemically modified pegRNA and prime editor mRNA, resulting in successful PE in vivo .”
Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy
Porcari, A., Sinagra, G., Gillmore, J. D., Fontana, M., & Hawkins, P. N. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.001 · Cited by 39
“In a quantum leap beyond gene silencing, profound and sustained suppression of TTR production has recently been achieved with just a single administration of NTLA-2001, the first CRISPR-Cas9-based gene-editing therapy to have ever been delivered in vivo [57].”
BackgroundSelf-citationGene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 47
“75 Delivery methods also offer opportunities for enhancing cell-type specificity.”
Gene Therapies for Monogenic Autism Spectrum Disorders
Weuring, W. J., Geerligs, J., & Koeleman, B. P. C. (2021) · Genes · doi:10.3390/genes12111667 · Cited by 41
“By introducing DSBs in the coding region of TTR, overall TTR levels were reduced up to 28 days after transfusion [48].”
BackgroundBeyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies
Pieroni, M., Ciabatti, M., Saletti, E., Tavanti, V., Santangeli, P., Martinese, L., Liïstro, F., Olivotto, I., & Bolognese, L. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01778-2 · Cited by 34
Prevalence and Subtypes of Tenosynovial Amyloid in Patients Undergoing Carpal Tunnel Release
DiBenedetto, M. R., Soong, M. C., Hunter, A., et al. (2022) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2022.02.013 · Cited by 34
Metzger, J. M., Wang, Y., Neuman, S. S., Snow, K. J., Murray, S. A., Lutz, C. M., Bondarenko, V., Felton, J., Gimse, K., Xie, R., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121959 · Cited by 38
Hereditary Angioedema: A Review of the Current and Evolving Treatment Landscape
Betschel, S., Banerji, A., Busse, P. J., et al. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.017 · Cited by 34
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
Song, N., Chu, Y., Li, S., Fan, X., Tang, J., Li, H., Tao, R., Li, F., Li, J., Yang, D., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202306634 · Cited by 36
Monda, E., Bakalakos, A., Rubino, M., Verrillo, F., Diana, G., Michele, G. D., Altobelli, I., Lioncino, M., Perna, A., Falco, L., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010687 · Cited by 38
Zhou, X., Li, D., Xia, S., Ma, X., Li, R., Mu, Y., Liu, Z., Zhang, L., Zhou, Q., Zhuo, W., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.018 · Cited by 39
Costabile, G., Conte, G., Brusco, S., Savadi, P., Miro, A., Quaglia, F., d’Angelo, I., & Ungaro, F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030347 · Cited by 42
“Recently, LNPs were employed in a clinical trial to deliver Cas9 mRNA and guide RNA for editing the gene causing transthyretin amyloidosis [162].”
MethodMerlin, J. P. J., & Abrahamse, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117516 · Cited by 39
Lipid-peptide nanocomplexes for mRNA delivery in vitro and in vivo
Grant-Serroukh, D., Hunter, M. R., Maeshima, R., Tagalakis, A. D., Aldossary, A. M., Allahham, N., Williams, G. R., Edbrooke, M. R., Desai, A. S., & Hart, S. L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.018 · Cited by 40
An engineered xCas12i with high activity, high specificity and broad PAM range
Zhang, H., Kong, X., Xue, M., Hu, J., Wang, Z., Wei, Y., Wang, H., Zhou, J., Zhang, W., Xu, M., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac052 · Cited by 60
Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection
Xue, Y., Wang, C., Li, H., Du, S., Zhong, Y., Zhang, Y., Wang, S., Guo, K., Hou, X., Kang, D. D., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417097 · Cited by 34
Structure and engineering of miniature Acidibacillus sulfuroxidans Cas12f1
Wu, Z., Liu, D., Pan, D. Y., Yu, H., Shi, J. F., Ma, J., Fu, W., Wang, Z., Zheng, Z., Qu, Y., et al. (2023) · Nature Catalysis · doi:10.1038/s41929-023-00995-4 · Cited by 34
Raigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 45
“153 These findings mark a significant milestone as NTLA-2001 represents the first systemically administered, in vivo CRISPR-Cas9 therapeutic to achieve targeted gene editing in humans.”
Epigenetic Alterations in Podocytes in Diabetic Nephropathy
Sugita, E., Hayashi, K., Hishikawa, A., & Itoh, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759299 · Cited by 38
Curative Cell and Gene Therapy for Osteogenesis Imperfecta
Schindeler, A., Lee, L. R., O’Donohue, A. K., Ginn, S. L., & Munns, C. F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4549 · Cited by 44
“editing and has strong emerging clinical trial data outside of OI((105)) • Cas9n approaches((102)) may allow for more specific allele targeted disruption • Small indels created by NHEJ may”
BackgroundLncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer’s Disease
Liu, Y., Chen, X., Che, Y., Li, H., Zhang, Z., Peng, W., & Yang, J. (2022) · Aging and Disease · doi:10.14336/ad.2021.1119 · Cited by 37
“Therefore, Cas9 can deliver any fusion protein and RNA to any dsDNA sequence, which has great potential for research and modification of organisms [119].”
BackgroundGene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 36
Progress in nanoparticle-based regulation of immune cells
Fan, Y.-N., Zhao, G., Zhang, Y., Ye, Q., Sun, Y., Shen, S., Liu, Y., Xu, C., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2022-0047 · Cited by 36
Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34
Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments
Garaizar, A., Díaz‐Oviedo, C. D., Zablowsky, N., Rissanen, S., Köbberling, J., Sun, J., Steiger, C., Steigemann, P., Mann, F. A., & Meier, K. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404555121 · Cited by 40
“…the onset of our study, we conducted direct coexistence simulations (DC) (31–33) to investigate how LP01 (34), a CIL currently used in a clinical - stage gene editing study (35), along with cholesterol, distearoylphosphatidylcholine (DSPC), and RNA, arranges within an LNP in an acidic environment.”
Targeted Delivery of mRNA with Polymer–Lipid Nanoparticles for In Vivo Base Editing
Chen, Q., Chang, Y., He, X., Ding, Y., Wang, R., Luo, R., Yuan, J., Chen, J., Zhong, G., Yang, H. Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14041 · Cited by 36
The impact of rare diseases on the quality of life in paediatric patients: current status
Dumbuya, J. S., Zeng, C., Deng, L., Li, Y., Chen, X., Ahmad, B., & Lü, J. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1531583 · Cited by 50
Haley, R. M., Padilla, M. S., El-Mayta, R. D., Joseph, R. A., Weber, J. A., Figueroa‐Espada, C. G., Mukalel, A. J., Ricciardi, A. S., Palanki, R., Geisler, H. C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16617 · Cited by 42
Mammalian antiviral systems directed by small RNA
Takahashi, T., Heaton, S. M., & Parrish, N. F. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010091 · Cited by 37
Brot, S., Thamrin, N. P., Bonnet, M., Francheteau, M., Patrigeon, M., Belnoue, L., & Gaillard, A. (2022) · Cells · doi:10.3390/cells11101596 · Cited by 35
“Otherwise, other approaches provide clinical proof of concept for in vivo CRISPR–Cas9-mediated gene editing as a therapeutic strategy [74], especially for familial forms of PD.”
BackgroundPre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 37
McCann, J. L., Sosa‐Miranda, C. D., Guo, H., Reshke, R., Savard, A., Buzatto, A. Z., Taylor, J. A., Li, L., & Gibbings, D. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12220 · Cited by 38
“…to transiently introduce RNA and DNA into cells by transfection and related methods has become a mainstay of much biological research, and the foundation of new therapeutics using siRNA (ONPATTRO) (Adams et al., 2018), mRNA vaccines for COVID-19, and CRISPR gene editing (Gillmore et al., 2021).”
Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018
Ney, S., Ihle, P., Ruhnke, T., Günster, C., Michels, G., Seuthe, K., Hellmich, M., & Pfister, R. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02114-y · Cited by 34
“Additionally, highly effective drugs for ATTR are at advanced stages of clinical evaluation (HELIOS-B [NCT04153149], CARIOTTRansform [NCT04136171] and [12]).”
BackgroundCarneiro, S. P., Greco, A., Chiesa, E., Genta, I., & Merkel, O. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2185220 · Cited by 38
“Plasmid DNA encoding for Cas9 and sgRNA Pcsk9 Liver Intravenous injection [94] Cas9 mRNA and sgRNA DMD1 Hindlimb muscle Intravenous injection [54] Cas9 mRNA and sgRNA Pten; Pcsk9; Plk1; PLK1 Multiple Organs Intravenous injection [105] Cas9 mRNA and sgRNA PCSK9 Liver Intravenous injection [95] Cas9 mRNA and sgRNA Pah;…”
MethodPAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Hiramoto, T., Kashiwakura, Y., Hayakawa, M., Baatartsogt, N., Kamoshita, N., Abe, T., Inaba, H., Nishimasu, H., Uosaki, H., Hanazono, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00286-w · Cited by 31
“Alternatively, ef fi cient genome editing in the liver hepatocyte could be achieved by lipid nanoparticle (LNP)-based intravenous delivery of Cas9 mRNA in a human clinical trial 54 .”
Pinjala, P., Tryphena, K. P., Kulkarni, A., Goswami, P. G., & Khatri, D. K. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230128 · Cited by 34
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“At 4 weeks post-injection, patients receiving the higher dose experienced an 87% reduction in TTR , with no off-target editing and only mild adverse effects [196].”
BackgroundAffordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative
Rueda, J., Beriaín, Í. D. M., & Montoliu, L. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0042 · Cited by 50
“This company has released gene therapies for two unrelated rare diseases, hereditary transthyretin amyloidosis 33 and hereditary angioedema, 34 which are currently in clinical trials.”
A Smart DNA Nanoframework Enables Synergistic Photodynamic Therapy of Pancreatic Cancer
Song, N., Li, H., Tao, R., Huang, Y. H., Zhang, R., Guo, J.-F., Liu, P., Yao, C., & Yang, D. (2025) · Advanced Materials · doi:10.1002/adma.202416161 · Cited by 32
Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del
Deiman, F. E., Bömer, N., van der Meer, P., & Beverborg, N. G. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00558-x · Cited by 35
Xu, C., Jiang, S., Ma, X., Jiang, Z., Pan, Y., Li, X., Zhang, L., Zhou, H., Chen, S., Xing, X., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03404-0 · Cited by 34
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



